US patent sought for obesity susceptibility test:
This article was originally published in Clinica
Executive Summary
GeneLink has filed a US patent application covering its non-invasive genetic test for assessing an individual's susceptibility to obesity. The test, which measures single-nucleotide polymorphisms in several genes, could help nutritional companies and those involved in medical, health and weight loss management offer an earlier and improved approach to obesity management, claims the Margate, New Jersey firm. Sample collection involves mailing saliva swabs to a testing laboratory. John De Phillipo, GeneLink's, chairman and CEO says the firm has already "received an overwhelming response from major weight loss and nutritional companies seeking distribution".